Preparation method of flat chrysanthemum Panax notoginseng composition and its application in lowering uric acid
Through tryptophan ascorbic acid eutectic solvent and ultrasonic extraction process, the problems of Chinese medicine extraction efficiency and stability are solved, and efficient and environmentally friendly preparation of traditional Chinese medicine compositions is achieved, suitable for large-scale production, and the uric acid level is significantly reduced.
Patent Information
- Application Number
- CN202411233723.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-09-04
AI Technical Summary
The existing Chinese medicine extraction process has problems such as low extraction efficiency, high impurity content, poor stability and high production costs, making it difficult to achieve low-cost large-scale production, especially when preparing Chinese medicine compositions containing multiple components.
Tryptophan ascorbic acid eutectic solvent is used as the extraction solvent, and through microwave reaction and ultrasonic extraction technology, combined with constant temperature drying and centrifugal filtration, the extraction efficiency of Panax notoginseng, pale bamboo leaves and citrus cerevisiae and polyphenol compounds are improved. stability.
It has achieved efficient extraction of traditional Chinese medicine compositions, good stability, significant uric acid reduction effect, simple process, green and environmentally friendly, and suitable for large-scale production.
Smart Images

Figure CN118717907B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of preparation of traditional Chinese medicine compositions, and in particular to a preparation method of a procumbent chrysanthemum and notoginseng composition and application thereof in reducing uric acid. Background Art
[0002] With the improvement of people's living standards, hyperuricemia has become the "fourth high" after hypertension, hyperlipidemia and hyperglycemia. Hyperuricemia not only causes gout, but may also lead to serious health problems such as renal failure. Modern medicine has made some progress in the diagnosis and treatment of uric acid reduction, but most of them are Western medicine treatments, which have side effects such as liver and kidney damage and bone marrow suppression. Traditional Chinese medicine has the advantages of one drug with multiple effects and a wide range of targets for the treatment of hyperuricemia, providing patients with a new treatment option.
[0003] As a traditional medicinal and edible plant, Glehnia littoralis has anti-inflammatory, analgesic and uric acid-lowering effects, and its extract can reduce the production of uric acid; Bamboo leaves are used in traditional Chinese medicine to clear away heat, relieve restlessness, promote diuresis and relieve stranguria, which can indirectly help improve the clinical symptoms of patients with hyperuricemia; and Hovenia dulcis is another traditional Chinese medicinal material that is used to treat a variety of diseases, including hyperuricemia. Glehnia littoralis, Bamboo leaves and Hovenia dulcis are combined with relevant auxiliary medicinal materials to make oral preparations, which are easy to take and have high compliance.
[0004] The preparation of oral Chinese medicine preparations usually involves Chinese medicine extraction technology. Appropriate extraction technology and solvents are critical to ensure the extraction efficiency and activity of active ingredients in Chinese medicine. Although the traditional water extraction method is simple to operate, it often faces the problems of low extraction efficiency and high impurity content; while the organic solvent extraction method can improve the extraction efficiency, the solvent used may have safety and environmental protection issues, and additional separation and detection steps may be required in subsequent processing, which increases costs. In addition, the Chinese medicine extracts obtained by the traditional heating and stirring and water bath extraction methods also have the problems of poor stability and easy decomposition of active substances. Not only are they difficult to put into large-scale production, but their uric acid-lowering effect will also be greatly reduced.
[0005] Patent CN117357635A discloses a method for extracting active ingredients of Chinese medicinal materials such as Panax notoginseng, Bamboo leaves and Celery seeds by supercritical extraction process. The Chinese medicine composition prepared by this method can be used to reduce uric acid, but the supercritical extraction process has high requirements for equipment and high production costs, making it difficult to achieve low-cost large-scale production. The document Li Minghui. Application of natural deep eutectic solvent in the extraction of Panax notoginseng saponin components and study on the activity of its solution [D]. Kunming University of Science and Technology, 2023. discloses a method for extracting saponin components in Panax notoginseng using natural deep eutectic solvent. The saponin active ingredients are extracted from Panax notoginseng by ultrasound-assisted natural deep eutectic solvent, but the extraction of other active ingredients in Panax notoginseng is not studied, nor is the extraction of Chinese medicine compositions containing Panax notoginseng further developed. It is not suitable for the extraction and processing of Chinese medicine compositions containing multiple components. Summary of the invention
[0006] In order to solve the above technical problems, the present invention provides a preparation method of a Panax notoginseng procumbens composition and its application in lowering uric acid. Panax notoginseng procumbens, lophatherum gracile and Hovenia dulcis are used as main raw materials, and a tryptophan ascorbic acid low eutectic solvent is used as an extraction solvent, which can improve the extraction efficiency and the stability of polyphenol compounds.
[0007] A method for preparing a flat-lying chrysanthemum Panax notoginseng composition comprises the following steps:
[0008] S1: Pre-treating a component including 15wt%-50wt% of Radix Notoginseng, 10wt%-30wt% of Folium Glehniae, 15wt%-25wt% of Fructus Hoveniae and 1wt%-20wt% of auxiliary medicinal materials to obtain a raw material powder, wherein the auxiliary medicinal materials include at least one of celery seeds, mulberry leaves, Poria cocos, radix puerariae and barley seedlings;
[0009] S2: Tryptophan and ascorbic acid are mixed with at least one of ultrapure water, methanol, ethanol, and acetonitrile in a molar ratio of 1:(0.25-2), stirred and subjected to microwave reaction, then evaporated until no distillate is evaporated, and dried at a constant temperature to obtain a low eutectic solvent;
[0010] S3: adding water to the low eutectic solvent to obtain a diluent, wherein the concentration of the diluent is 10%-50%, mixing the raw material powder in step S1 with the diluent, performing ultrasonic extraction, and then centrifuging and filtering to obtain a procumbent chrysanthemum notoginseng composition.
[0011] It should be noted that, in the present invention, "molar ratio" means "ratio of the amount of a substance".
[0012] The solvent used in the preparation process of the low eutectic solvent can be at least one of ultrapure water, methanol, ethanol, and acetonitrile, for example, it can be a mixture of ultrapure water and methanol, but the use of ultrapure water has the best effect; the amount of solvent used can vary according to the amount of tryptophan and ascorbic acid fed and the size of the selected reaction bottle, and the preferred solid-liquid mass ratio is 4:1.
[0013] As a further improvement of the above scheme, the raw material components in step S1 include 40wt% of Notoginseng procumbentum, 20wt% of Lophatherum gracile, 20wt% of Hovenia dulcis, 10wt% of Celery Seed, 5wt% of Mulberry Leaf and 5wt% of Pueraria lobata.
[0014] As a further improvement of the above scheme, the molar ratio of tryptophan to ascorbic acid in step S2 is 1:1.
[0015] As a further improvement of the above scheme, in step S2, the stirring rate is 400 r / min-600 r / min, the stirring time is 6 h-9 h, and the stirring temperature is 30° C.-60° C.
[0016] As a further improvement of the above scheme, in step S2, the microwave reaction temperature is 30°C-50°C, the microwave frequency is 1GHz-5GHz, the microwave power is 600W-1000W, and the microwave time is 40min-2h.
[0017] As a further improvement of the above scheme, the temperature of the evaporation treatment in step S2 is 50°C-80°C, and the pressure is -0.04MPa--0.10MPa; the temperature of the constant temperature drying does not exceed 80°C.
[0018] As a further improvement of the above scheme, the raw material powder is mixed with the low eutectic solvent diluent in a solid-liquid ratio of 1g:10mL-80mL.
[0019] As a further improvement of the above scheme, the parameters of the ultrasonic extraction in step S3 are: power 100W-500W, time 30min-120min, temperature 40°C-80°C.
[0020] As a further improvement of the above scheme, the parameters of the centrifugal treatment in step S3 are a rotation speed of 5000 r / min-10000 r / min and a treatment time of 5 min-15 min; and the pore size of the filter membrane in the filtration treatment is not greater than 0.45 μm.
[0021] As a further improvement of the above scheme, the preparation method of the flat-lying chrysanthemum Panax notoginseng composition comprises the following steps:
[0022] S1: pre-treating 40wt% of Radix Notoginseng procumbens, 20wt% of Lophatherum gracile, 20wt% of Hovenia dulcis, 10wt% of Celery Seed, 5wt% of Mulberry Leaf, and 5wt% of Puerariae Radix to obtain a raw material powder having a particle size of no more than 0.18 mm;
[0023] S2: Put tryptophan and ascorbic acid into the reactor in a molar ratio of 1:1, add ultrapure water with a total mass of 1 / 4 of tryptophan and ascorbic acid, and then stir for 8 hours at a stirring rate of 500 r / min and a stirring temperature of 40°C, and then microwave react for 1 hour at a temperature of 40°C, a frequency of 2.4 GHz, and a power of 800 W to obtain a first mixed solution; evaporate the first mixed solution at a temperature of 60°C and a pressure of -0.080 MPa until no distillate is evaporated to obtain a second mixed solution; place the second mixed solution in a vacuum constant temperature drying oven and dry it at a constant temperature of 50°C until the weight is constant, thereby obtaining a low eutectic solvent;
[0024] S3: The low eutectic solvent is diluted with water to obtain a dilution with a concentration of 30wt%, the raw material powder and the dilution are mixed at a solid-liquid ratio of 1g:30mL, and then ultrasonic extraction is performed with an ultrasonic power of 400W, a temperature of 50°C, and a processing time of 60min to obtain a plant extract; the plant extract is centrifuged with a speed of 8000r / min and centrifuged for 15min, the supernatant is filtered using a filter membrane with a pore size of 0.45μm to obtain a procumbent Chrysanthemum notoginseng composition.
[0025] As a further improvement of the above scheme, step S2 is carried out in a protective gas atmosphere, and the protective gas atmosphere refers to an anti-oxidation protective atmosphere, such as a gas atmosphere formed by one or more inert gases such as helium, argon, nitrogen, carbon dioxide, etc.
[0026] A uric acid lowering application of a Panax notoginseng composition prepared by any of the above preparation methods, comprising using the Panax notoginseng composition as a raw material to prepare an oral preparation for lowering uric acid.
[0027] As a further improvement of the above scheme, the oral preparation is a solution, which is prepared by the following method:
[0028] 80-96 parts of the flat chrysanthemum Panax notoginseng composition, 5-10 parts of microcrystalline cellulose, 1-4 parts of a sweetener, 1-3 parts of a flavoring agent, and 1-3 parts of a food thickener are stirred for 20 min-40 min to obtain a uric acid-lowering composition, and the uric acid-lowering composition is filled in a bottle sterilized at high temperature, and sterilized again after filling to obtain a uric acid-lowering oral liquid;
[0029] The sweetener is at least one of aspartame, xylitol, sorbitol, mannitol, maltitol and sodium cyclamate;
[0030] The flavoring agent is at least one of citric acid, taurine, propolis, potassium carbonate, glycyrrhizic acid and stevioside;
[0031] The food thickener is at least one of gum arabic, agar, sodium alginate, carrageenan, pectin, xanthan gum, sodium carboxymethyl cellulose and sodium carboxymethyl starch.
[0032] As a further improvement of the above scheme, the oral preparation is a powder, which is prepared by the following method:
[0033] The uric acid lowering oral liquid is heated and passed through a spray dryer, wherein the spray pressure of the spray dryer is 5 kPa-20 kPa and the air volume is 0.2 m 3 / min-1m 3 / min, the solution flow rate is 80mL / h-400mL / h, the inlet temperature is 90℃-125℃, and the outlet temperature is 60℃-95℃ to obtain uric acid lowering powder.
[0034] As a further improvement of the above scheme, the oral preparation is an effervescent tablet, which is prepared by the following method:
[0035] 40-70 parts of uric acid-lowering powder, 1-5 parts of disintegrants and 1-3 parts of binders are stirred for 20-60 minutes by weight to ensure that all ingredients are fully mixed to avoid agglomeration; then 10-30 parts of effervescent agent and 1-5 parts of lubricant are added, and stirred for 20-60 minutes to ensure that they are fully mixed to avoid excessive local concentration; after mixing, the mixture is put into a tablet press, and the tablet press equipment parameters are: a mold volume with a filling depth of 75%, a pre-compression pressure of 5MPa-215MPa, a compression pressure of 80MPa-200MPa, a holding time of 5s-20s, and a demoulding pressure of 5MPa-10MPa; and uric acid-lowering effervescent tablets are obtained by pressing;
[0036] The disintegrant is at least one of cross-linked sodium carboxymethyl cellulose and cross-linked polyvinylpyrrolidone;
[0037] The binder is at least one of polyvinyl pyrrolidone and povidone;
[0038] The effervescent agent is at least one of sodium bicarbonate and citric acid;
[0039] The lubricant is at least one of magnesium stearate, talcum powder, sodium chloride and sodium lauryl sulfate.
[0040] Compared with the prior art, the beneficial effects of this application are:
[0041] (1) Based on the combination of traditional Chinese medicine theory and modern scientific research, Glehnia littoralis, Glehnia littoralis and Hovenia dulcis were selected as the main raw materials, supplemented with celery seeds, mulberry leaves and Pueraria root, to form a Chinese medicine composition with uric acid lowering effect. Glehnia littoralis, as a traditional medicinal and edible plant, has anti-inflammatory, analgesic and anti-gout effects; Glehnia littoralis is usually used to clear heat, promote diuresis and remove dampness, which can indirectly help improve the clinical symptoms of patients with hyperuricemia; and the dihydroisoflavones in Hovenia dulcis have uric acid lowering effects. The various ingredients cooperate with each other, and the safety and uric acid lowering effect of its oral preparation have been verified by mouse experiments.
[0042] (2) Using a low eutectic solvent diluent formed by tryptophan and ascorbic acid as an extraction solvent to extract Chinese medicinal components such as Panax notoginseng, not only is the preparation process simple and environmentally friendly, but it can also improve the extraction efficiency of total polyphenols and chlorogenic acid in Chinese medicinal components. The oral liquid made from the extracted Panax notoginseng composite material has stable active ingredients, good uric acid-lowering effect, few side effects, and can also relieve inflammation in the body. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0044] Figure 1 1 is a quantum chemical characterization diagram of the tryptophan ascorbic acid deep eutectic solvent obtained in Example 1 of the present invention, wherein (a) is a structure optimization diagram, (b) is an ESP potential analysis diagram, and (c) is an IRI analysis diagram;
[0045] Figure 2 1 is a quantum chemical characterization diagram of the tryptophan ascorbic acid low eutectic solvent and chlorogenic acid obtained in Example 1 of the present invention, wherein (a) is a structure optimization diagram, (b) is an ESP potential analysis diagram, and (c) is an IRI analysis diagram. DETAILED DESCRIPTION
[0046] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application more clearly understood, the present application is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application.
[0047] The weight of the relevant components mentioned in the embodiment description of the present application can not only refer to the specific content of each component, but also represent the proportional relationship between the weights of the components. Therefore, as long as the content of the relevant components is proportionally enlarged or reduced according to the embodiment description of the present application, it is within the scope disclosed in the embodiment description of the present application. Specifically, the mass described in the embodiment description of the present application can be a mass unit known in the chemical industry such as μg, mg, g, kg, etc.
[0048] In order to facilitate the understanding of the present invention, the present invention will be described more comprehensively and meticulously below in conjunction with the accompanying drawings and preferred embodiments of the present invention, but the protection scope of the present invention is not limited to the following specific embodiments.
[0049] Unless otherwise defined, all professional terms used below have the same meanings as those generally understood by those skilled in the art. The professional terms used herein are only for the purpose of describing specific embodiments and are not intended to limit the scope of protection of the present invention.
[0050] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.
[0051] Example 1
[0052] S1: Pre-treating components including 40 wt% of Notoginseng procumbens, 20 wt% of Lophatherum gracile, 20 wt% of Hovenia dulcis, 10 wt% of Celery Seed, 5 wt% of Mulberry Leaf, and 5 wt% of Puerariae Radix to obtain a raw material powder having a particle size of no more than 0.18 mm;
[0053] S2: Put tryptophan and ascorbic acid into the reactor in a molar ratio of 1:1, add ultrapure water with a total mass of 1 / 4 of tryptophan and ascorbic acid, and then stir for 8 hours at a stirring rate of 500 r / min and a stirring temperature of 40°C, and then microwave react for 1 hour at a temperature of 40°C, a frequency of 2.4 GHz, and a power of 800 W to obtain a first mixed solution; the first mixed solution is evaporated at a temperature of 60°C and a pressure of -0.080 MPa until no distillate is evaporated to obtain a second mixed solution; the second mixed solution is placed in a vacuum constant temperature drying oven and dried at a constant temperature of 50°C until the weight is constant, thereby obtaining a low eutectic solvent;
[0054] S3: dilute the low eutectic solvent obtained in step S2 with water to obtain a dilution with a concentration of 30wt%, use the dilution as the extraction solvent, mix the raw material powder obtained in step S1 with the extraction solvent at a solid-liquid ratio of 1g:30mL, and then use ultrasonic extraction with an ultrasonic power of 400W, a temperature of 50°C, and an extraction time of 60min to obtain a plant extract; centrifuge the plant extract with a speed set to 8000r / min, centrifuge for 15min, take the supernatant and filter it with a filter membrane with a pore size of 0.45μm to obtain a procumbent Chrysanthemum notoginseng composition.
[0055] Test Example 1: Quantum Chemical Computational Analysis of Tryptophan-Ascorbic Acid Deep Eutectic Solvent
[0056] Figure 1 The quantum chemical characterization diagram of the tryptophan ascorbic acid low eutectic solvent obtained in Example 1, wherein (a) is a structure optimization diagram, (b) is a surface electrostatic potential (Electrostatic surface potential, ESP) potential analysis diagram, and (c) is an interaction region indicator function (Interaction region indicator function, IRI) analysis diagram.
[0057] like Figure 1 As shown in (a), the geometry optimization and frequency calculation of the tryptophan ascorbic acid low eutectic solvent have converged, and no imaginary frequency was found, indicating that the current structure is at the local minimum point of the potential energy surface and can exist stably. The hydroxyl group on the carboxyl group of ascorbic acid interacts with the carbonyl group of tryptophan through hydrogen bonding, and the carbonyl group of ascorbic acid interacts with the hydroxyl group on the carboxyl group of tryptophan through hydrogen bonding, and the interaction distances are 1.71995Å and 1.85463Å, respectively, which are much shorter than the van der Waals radius.
[0058] like Figure 1 As shown in (b), the formation mechanism of the tryptophan-ascorbic acid low eutectic solvent was qualitatively analyzed by surface electrostatic potential (ESP), and the depth of color represents different electric potentials. For tryptophan, the carbonyl region is electropositive, the hydroxyl region is electronegative, and a large area surrounding the nitrogen atom is electropositive; for ascorbic acid, the carbonyl region is electropositive, and the hydroxyl region on the carboxyl group is electronegative. After the formation of the low eutectic solvent, the electronegative region of tryptophan and the electronegative region of ascorbic acid attract each other, and the electronegative region of tryptophan and the electronegative region of ascorbic acid attract each other to form a stable low eutectic solvent.
[0059] like Figure 1As shown in (c), the interaction region indicator function (IRI) is used to characterize the van der Waals force, hydrogen bond, and steric repulsion of the molecule. Different color blocks represent different intermolecular forces. The small discs in the ring structure represent steric hindrance. The stronger the steric hindrance, the more difficult it is for the atoms in the corresponding two regions to attract each other. The small discs outside the ring structure represent interactions such as attraction, steric hindrance, or strong attraction, such as hydrogen bonds; the large block-shaped transitional areas represent van der Waals weak interactions. There are large block-shaped interaction force areas between tryptophan and ascorbic acid, indicating that there is a van der Waals force between them, and there are small discs between the hydroxyl and carbonyl groups. According to existing research, it can be fully demonstrated that there is a strong hydrogen bond interaction force between these two sites.
[0060] Example 2
[0061] The concentrations of the diluent in step S2 were replaced with 10wt%, 20%, 40% and 50% respectively, and the remaining step parameters were the same as those in Example 1, to prepare Panax notoginseng compositions with different extraction solvents.
[0062] Example 3
[0063] The ultrasonic extraction time in step S3 was replaced with 30 min, 90 min and 120 min respectively, and the parameters of other steps were the same as those in Example 1, so as to prepare procumbent chrysanthemum notoginseng compositions with different extraction times.
[0064] Example 4
[0065] The feed ratio of tryptophan and ascorbic acid in step S2 was replaced with 2:1, and the parameters of other steps were the same as those in Example 1 to prepare a procumbent chrysanthemum notoginseng composition.
[0066] Example 5
[0067] The feed ratio of tryptophan and ascorbic acid in step S2 was replaced with 3:1, and the parameters of other steps were the same as those in Example 1 to prepare a procumbent chrysanthemum notoginseng composition.
[0068] Example 6
[0069] The feed ratio of tryptophan and ascorbic acid in step S2 was replaced with 1:2, and the parameters of other steps were the same as those in Example 1 to prepare a procumbent chrysanthemum notoginseng composition.
[0070] Comparative Example 1
[0071] The extraction solvent in step 2 was replaced with ultrapure water, and the ultrasonic extraction time in step 3 was replaced with 30 min, 60 min, 90 min and 120 min respectively. The parameters of other steps were the same as those in Example 1, and a combination of Panax notoginseng with different extraction solvents and extraction times was prepared.
[0072] Comparative Example 2
[0073] The extraction solvent in step 2 was replaced with ethanol solutions with concentrations of 25wt%, 50wt%, 75wt% and 100wt%, respectively, and the remaining step parameters were the same as those in Example 1 to prepare Panax notoginseng procumbentus compositions with different extraction solvents.
[0074] Comparative Example 3
[0075] Tryptophan and ascorbic acid are put into the reactor at a molar ratio of 1:1, and ultrapure water is added to dissolve them to prepare a 30wt% ascorbic acid tryptophan mixed solution. The extraction solvent in step S3 of Example 1 is replaced with a 30wt% ascorbic acid tryptophan mixed solution. The remaining step parameters are the same as in Example 1 to obtain a flat chrysanthemum Panax notoginseng composition.
[0076] Comparative Example 4
[0077] Tryptophan and citric acid are put into a reactor in a molar ratio of 1:1, and then ultrapure water with a total mass of 1 / 4 of the tryptophan and citric acid is added, heated and stirred for 6 hours, the heating temperature is 55° C., and the magnetic stirring rate is 500 rpm; then, evaporation treatment is performed under the conditions of a temperature of 60° C. and a pressure of minus 0.08 MPa until no distillate is evaporated to obtain a tryptophan citric acid low eutectic solvent, water is added to the tryptophan citric acid low eutectic solvent to dilute it to a concentration of 30 wt%, and the remaining step parameters are the same as those in Example 1, to obtain a flat chrysanthemum Panax notoginseng composition.
[0078] Comparative Example 5
[0079] The citric acid in Comparative Example 4 was replaced by glycolic acid, and the remaining step parameters were the same as Comparative Example 4 to prepare a procumbent Chrysanthemum notoginseng composition.
[0080] Test Example 2: Detection of total polyphenols and chlorogenic acid content
[0081] The flat chrysanthemum Panax notoginseng compositions prepared in Examples 1-6 and Comparative Examples 1-5 were used as test solutions and tested according to the following method:
[0082] Total polyphenol yield test method:
[0083] The polyphenols were quantitatively analyzed using a UV-1900i series UV spectrophotometer at a wavelength of 765 nm;
[0084] Preparation of 10% Folin phenol reagent (freshly prepared): pipette 10 ml of Folin phenol and make up to 100 ml;
[0085] Preparation of 7.5% sodium carbonate solution: weigh 37.50g sodium carbonate and dissolve it in water, then make up to 500ml;
[0086] Gallic acid standard stock solution (1 mg / ml, freshly prepared): weigh 0.110 g of gallic acid monohydrate and dissolve it in water, and make up to 100 ml;
[0087] Gallic acid working solution: dilute the gallic acid standard stock solution into working solutions with concentrations of 0.01 mg / mL, 0.02 mg / mL, 0.03 mg / mL, 0.04 mg / mL and 0.05 mg / mL in sequence, and prepare them before use;
[0088] Take 1 ml of gallic acid working solution, water and 100-fold diluted test solution into a graduated test tube, add 5.0 ml of Folin phenol reagent respectively, shake well, react for 3-5 minutes, add 4.0 ml of 7.5% sodium carbonate solution and shake well, place at room temperature for 60 minutes and then measure, calculate the concentration of total polyphenols in the test solution, and then convert it according to the dilution factor of 100 times to obtain the actual concentration C1 after the extraction is completed, and then calculate the yield of total polyphenols according to Formula 1 based on the volume V of the extraction solvent and the mass M of the raw material powder:
[0089] Formula 1: .
[0090] Chlorogenic acid yield test method:
[0091] Select S501 liquid chromatograph and ODS C18 chromatographic column (4.6mm×250mm, 5μm); mobile phase: acetonitrile-0.5% acetic acid aqueous solution (10:90, V / V); detection wavelength 327nm; flow rate 0.5mL / min; column temperature 30℃; accurately weigh 8 mg of chlorogenic acid reference substance, place it in a 100mL volumetric flask, dilute it with the mobile phase, shake it well and make up to the scale to obtain a reference solution containing 80 μg / mL chlorogenic acid; take 1mL of the reference solution, dilute it 2, 4, 8 and 16 times respectively, to obtain 40, 20, 10 and 5 μg / mL standard solutions; take 1mL of the test solution, dilute it 15 times, pass it through a 0.45μm filter membrane, and the filtrate is used for liquid chromatography analysis. The analysis result is multiplied by 15 to obtain the concentration C2 of chlorogenic acid in the test solution. According to the volume V of the extraction solvent and the mass M of the raw material powder, the yield of chlorogenic acid is calculated according to formula 2:
[0092] Formula 2: .
[0093] The test results of the total polyphenol yield and chlorogenic acid yield of the extraction methods of Examples 1-6 and Comparative Examples 1-5 are shown in Table 1. The results show that the extraction effect of the deep eutectic solvent is better than that of water extraction and ethanol extraction, and the extraction effect of the tryptophan ascorbic acid deep eutectic solvent is better than that of the tryptophan citric acid deep eutectic solvent and the tryptophan glycolic acid deep eutectic solvent.
[0094]
[0095] Test Example 3: Quantum Chemical Computational Analysis of Tryptophan Ascorbic Acid Deep Eutectic Solvent and Chlorogenic Acid
[0096] The possible mechanism of the high extraction efficiency of polyphenols in the tryptophan ascorbic acid deep eutectic solvent system was studied through quantum chemical calculations. Taking chlorogenic acid as the calculation model, the form and intensity of the action of the tryptophan ascorbic acid deep eutectic solvent on it were analyzed.
[0097] The optimized structures of tryptophan ascorbic acid deep eutectic solvent and chlorogenic acid are as follows Figure 2 As shown in (a), both the geometry optimization and frequency calculation converged, and no imaginary frequency was found, indicating that the current structure is at the local minimum point of the potential energy surface and can exist stably. The distance between the carbonyl group of tryptophan and the hydroxyl group of chlorogenic acid is much shorter than the van der Waals radius, which indicates that there is a hydrogen bond interaction between the tryptophan ascorbic acid deep eutectic solvent and chlorogenic acid.
[0098] like Figure 2 As shown in (b), the carbonyl regions of tryptophan and chlorogenic acid are electronegative, while the hydroxyl group is electronegative. When forming a stable structure, the electronegative region of the tryptophan ascorbic acid eutectic solvent and the electronegative region of chlorogenic acid attract each other, and the overall electrostatic potential is close to 0, thus forming a stable structure.
[0099] Interaction region indicator function analysis of tryptophan ascorbic acid deep eutectic solvent and chlorogenic acid Figure 2 As shown in (c), there are large block-shaped interaction regions between the tryptophan ascorbic acid low eutectic solvent and chlorogenic acid, indicating that there is a van der Waals force between them; at the same time, there are small discs between the carbonyl group in the tryptophan ascorbic acid low eutectic solvent and the hydroxyl group of chlorogenic acid, which means that there is a strong hydrogen bond interaction force between them at these two sites, which helps the formation and stability of the entire system. Structural optimization, ESP and IRI can explain why the yield of chlorogenic acid and total polyphenols in the tryptophan ascorbic acid low eutectic solvent system is higher.
[0100] Example 7
[0101] According to weight proportions, 85 parts of the Notoginseng flatus composition obtained in Example 1, 8 parts of microcrystalline cellulose, 1 part of maltitol, 1 part of xylitol, 3 parts of potassium carbonate and 2 parts of sodium alginate were taken and stirred for 40 minutes to obtain a uric acid lowering composition solution, which was filled into bottles sterilized at high temperature and sterilized again after filling to obtain a uric acid lowering oral liquid.
[0102] Comparative Example 6
[0103] Using the notoginseng flatus composition obtained by water extraction for 60 minutes in Comparative Example 1 as a raw material, a uric acid-lowering oral liquid was prepared according to the method of Example 7.
[0104] Comparative Example 7
[0105] Using the Chrysanthemum Notoginseng composition obtained by extraction with 50wt% ethanol for 60 minutes in Comparative Example 2 as a raw material, a uric acid-lowering oral liquid was prepared according to the method of Example 7.
[0106] Comparative Example 8
[0107] Using the Chrysanthemum Notoginseng composition obtained in Comparative Example 3 using a tryptophan ascorbic acid mixed solution as the extraction solvent as a raw material, a uric acid-lowering oral liquid was prepared according to the method of Example 7.
[0108] Test Example 4: Effect of exposure time under natural light at room temperature on the total polyphenol content of uric acid-lowering oral solution
[0109] The uric acid lowering oral liquids prepared in Example 7 and Comparative Examples 6-8 were used as samples. After being placed under natural light at room temperature for 2 weeks, 1 month, 2 months and 4 months, the total polyphenol content in the samples was detected. The results are shown in Table 2.
[0110]
[0111] The results show that the total polyphenol content in the uric acid-lowering oral liquid gradually decreases over time. Compared with the uric acid-lowering oral liquids prepared in Comparative Examples 6, 7, and 8, the total polyphenol content in the uric acid-lowering oral liquid prepared in Example 7 decreases the least. The stability of the polyphenol compounds in the raw materials in the preparation is improved, making it more suitable for long-term storage.
[0112] Test Example 5: Study on the effect of uric acid lowering oral solution on uric acid lowering in mice with high uric acid
[0113] 1. Reagents and medicinal materials
[0114] SPF male KM mice were purchased from Hunan Slake Jingda Experimental Animal Co., Ltd.; hypoxanthine (biochemical reagent): Shanghai Xushuo Biotechnology Co., Ltd.; XOD (25 U) (biochemical reagent): Sigma; chromatographically pure acetonitrile and potassium oxonate: Merck Chemical Technology (Shanghai) Co., Ltd.; physiological and biochemical index detection and antioxidant enzyme activity detection kits: Nanjing Jiancheng Bioengineering Institute; other reagents were domestically produced analytical grade.
[0115] 2. Experimental Methods
[0116] 60 SPF male KM mice were randomly divided into 6 groups after the feeding adaptation period, namely normal group, model group, positive control group and three experimental groups of Example 7, Comparative Example 6 and Comparative Example 8. Free diet, ambient temperature and lighting time were controlled as usual without special requirements. The experimental period was 2 weeks. Except for the normal group, the other 5 groups were gavaged with hypoxanthine 500 mg / kg·d and potassium oxonate 100 mg / kg·d on time every morning to build models; at the same time of modeling, except for the model group, the positive control group was given allopurinol 3 mg / kg·d, and the three experimental groups were gavaged with 200 mg / kg·d of uric acid-lowering oral solution obtained in Example 7, uric acid-lowering oral solution obtained in Comparative Example 6 and uric acid-lowering oral solution obtained in Comparative Example 8. All drugs were dissolved or diluted with 0.5% sodium carboxymethyl cellulose aqueous solution as solvent. During the whole experiment, the normal group was gavaged with the corresponding volume of 0.5% sodium carboxymethyl cellulose aqueous solution every day. After fasting for 12 hours from the night before to the day of execution, the last oral gavage was performed at the above dose, but water was not allowed. Blood was collected from the eyeballs 1 hour after oral gavage, and then the animals were killed by cervical dislocation, dissected, and the complete organs were weighed to calculate the organ coefficient.
[0117] Kits were used to measure the levels of blood uric acid (UA), creatinine (CRE), urea nitrogen (BUN) and inflammatory factors (IL-6, TNF-α, IL-10), hepatic xanthine oxidase (XOD) activity, superoxide dismutase (SOD) activity, catalase (CAT) activity and malondialdehyde (MDA) content.
[0118] 3. Experimental results
[0119] 3.1 Effects of uric acid-lowering oral solution on serum uric acid, creatinine, urea nitrogen and liver XOD activity in model mice
[0120] The liver coefficient was calculated by dividing the liver weight by the animal's body weight and multiplying by 100.
[0121] The kidney coefficient was calculated by dividing the kidney weight by the animal's body weight and then multiplying by 100.
[0122] The results are shown in Table 3. As can be seen from Table 3, the liver and kidney organ coefficients of the positive control group are the highest, indicating that allopurinol has certain side effects on liver and kidney, and the organ coefficients of the experimental group taking the uric acid-lowering oral liquid are close to the normal group, indicating that the edible safety of the uric acid-lowering oral liquid is high, and the side effects on liver and kidney are small. The blood uric acid level and liver XOD activity analysis of each group of mice can be found that compared with the normal group, the blood uric acid level and liver XOD activity of the model group mice are significantly increased, indicating that the high uric acid mouse model is successfully modeled. The blood uric acid level and liver XOD activity of the embodiment 7 group, the comparative example 6 group, and the comparative example 8 group are respectively reduced by 34.0%, 29.7%, 21.6% and 28.9%, 21.2%, 14.3% than the model group, indicating that the uric acid-lowering oral liquid can significantly reduce the blood uric acid level and liver XOD activity of mice, wherein the reduction degree of the embodiment 7 group is the most obvious, indicating that the uric acid-lowering oral liquid prepared by the embodiment 7 contains more liver XOD activity inhibitory components.
[0123] Table 3 Effects of uric acid-lowering oral solution on blood uric acid, creatinine, urea nitrogen and liver XOD activity in model mice
[0124]
[0125] Analysis of the creatinine level and liver urea nitrogen level of each group of mice showed that the creatinine and urea nitrogen levels of the positive control group were significantly higher than those of the other five groups, indicating that although allopurinol can reduce uric acid, it causes great damage to the kidneys, which is consistent with the result that the organ coefficient of the positive control group is high. The creatinine and urea nitrogen levels of the uric acid-lowering oral solution in the experimental group were significantly lower than those in the positive control group, among which the values of the Example 7 group were closest to the normal group, indicating that the uric acid-lowering oral solution prepared by using the tryptophan ascorbic acid low eutectic solvent diluent as the extraction solvent has a better uric acid-lowering effect and is highly safe for the liver and kidneys.
[0126] 3.2 Effect of uric acid-lowering oral solution on liver antioxidant capacity in model mice
[0127] Hepatic xanthine oxidase XOD catalyzes xanthine and hypoxanthine to produce uric acid, while producing reactive oxygen species ROS, which causes a sharp increase in the content of malondialdehyde (MDA) and oxidative damage in the body. As shown in Table 4, the liver MDA content of mice in the model group was significantly higher than that in the normal group, while the liver MDA content of the four treatment groups decreased significantly compared with the model group, and the degree of decrease in the experimental group was significantly greater than that in the positive control group; compared with the normal group, the SOD activity and CAT activity of mice in the model group decreased significantly, while they increased in the four treatment groups, and the increase in the experimental group was greater than that in the positive control group. It can be seen that the intervention of uric acid-lowering oral liquid can significantly reduce the degree of liver oxidation and increase the activity of antioxidant enzymes, and the effect is better than allopurinol.
[0128] Table 4 Effects of uric acid-lowering oral solution on the antioxidant capacity of liver in model mice
[0129]
[0130] 3.3 Effects of uric acid-lowering oral solution on inflammatory factors in model mice
[0131] Increased uric acid in the body activates the NLRP3 body and TLR4 / NF-κB signaling pathway to promote the expression of inflammatory factors, leading to inflammation of the body. As shown in Table 5, compared with the normal group, the serum proinflammatory factors IL-6 and TNF-α in the model group increased significantly, and the anti-inflammatory factor IL-10 content decreased significantly, indicating that the formation of high uric acid caused abnormal levels of cellular inflammatory factors. Compared with the model group, the serum IL-6 and TNF-α contents of mice in the four treatment groups decreased significantly, and the anti-inflammatory factor IL-10 content increased significantly, indicating that the intervention of allopurinol and uric acid-lowering oral liquid regulated the proinflammatory factors and anti-inflammatory factors in mice with high uric acid levels. In the experimental group, the 7th group had the best effect on the relief of inflammation caused by high uric acid levels.
[0132] Table 5 Effects of uric acid-lowering oral solution on inflammatory factors in model mice
[0133]
[0134] Example 8
[0135] The uric acid-lowering oral liquid obtained in Example 7 was heated and passed through a spray dryer with a spray pressure of 12 kPa and an air volume of 0.5 m 3 / min, the solution flow rate is 180mL / h, the inlet temperature is 103°C, and the outlet temperature is 90°C to obtain uric acid lowering oral powder.
[0136] Example 9
[0137] By weight, 63 parts of the uric acid lowering oral powder obtained in Example 8 were taken, 3 parts of cross-linked carboxymethyl cellulose sodium and 2 parts of povidone were added, and the mixture was stirred for 40 minutes. Subsequently, 18 parts of sodium bicarbonate, 12 parts of citric acid, and 2 parts of magnesium stearate were added, and the mixture was stirred for 40 minutes. After mixing, the mixture was put into a tablet press, and the parameters of the tablet press were set as follows: a mold volume with a filling depth of 75%, a pre-compression pressure of 30 MPa, a main compression pressure of 150 MPa, a holding time of 10 s, and a demolding pressure of 8 MPa. After the pressing was completed, uric acid lowering oral effervescent tablets were obtained.
[0138] The present invention uses Notoginseng procumbens, Bamboo Leaves, and Hovenia dulcis as main raw materials, uses a tryptophan ascorbic acid low eutectic solvent coupled with an ultrasonic extraction process to extract the plant raw materials, and can efficiently obtain a Notoginseng procumbens composition with uric acid lowering efficacy; by performing quantum chemical calculation analysis on the tryptophan ascorbic acid low eutectic solvent, the driving force for the formation of the low eutectic solvent is analyzed at the molecular level. From the experimental results, the use of a dilution of the tryptophan ascorbic acid low eutectic solvent as an extraction solvent not only has high extraction efficiency and is green and environmentally friendly, but also the uric acid lowering oral liquid made from the Notoginseng procumbens composition as a raw material has a good uric acid lowering effect, has little side effects on the liver and kidneys, and has a relieving effect on inflammation of the body caused by high uric acid.
[0139] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present application should be included in the protection scope of the present application.
Claims
1. A method for preparing a flat procumbent chrysanthemum Panax notoginseng composition, characterized in that: The following steps are involved: S1: Pre-treating components including 40wt% of Radix Notoginseng, 20wt% of Folium Lophatherum, 20wt% of Fructus Hoveniae, 10wt% of Celery Seed, 5wt% of Folium Mori and 5wt% of Radix Puerariae to obtain a raw material powder; S2: Tryptophan and ascorbic acid are mixed with ultrapure water in a molar ratio of 1:(0.25-2), stirred and subjected to microwave reaction, then evaporated until no distillate is evaporated, and dried at a constant temperature to obtain a low eutectic solvent; S3: adding water to the low eutectic solvent to obtain a dilution with a concentration of 10%-50%, mixing the raw material powder in step S1 with the dilution, performing ultrasonic extraction, and then centrifuging and filtering to obtain a procumbent chrysanthemum notoginseng composition.
2. The method for preparing the flat prostrate chrysanthemum Panax notoginseng composition as claimed in claim 1, characterized in that: The molar ratio of tryptophan to ascorbic acid in step S2 is 1:
1.
3. The method for preparing the flat prostrate chrysanthemum Panax notoginseng composition as claimed in claim 1, characterized in that: In step S2, the stirring rate is 400 r / min-600 r / min, the stirring time is 6 h-9 h, and the stirring temperature is 30° C.-60° C.
4. The method for preparing the flat prostrate chrysanthemum notoginseng composition according to claim 1, characterized in that: In the step S2, the microwave reaction temperature is 30° C.-50° C., the frequency is 1 GHz-5 GHz, the power is 600 W-1000 W, and the microwave time is 40 min-2 h.
5. The method for preparing the flat prostrate chrysanthemum Panax notoginseng composition as claimed in claim 1, characterized in that: The temperature of the evaporation treatment in step S2 is 50°C-80°C, and the pressure is -0.04MPa--0.10MPa; the temperature of the constant temperature drying does not exceed 80°C.
6. The method for preparing the flat prostrate chrysanthemum notoginseng composition according to claim 1, characterized in that: In the step S3, the raw material powder and the diluent are mixed in a solid-liquid ratio of 1 g: 10 mL-80 mL.
7. The method for preparing the flat prostrate chrysanthemum notoginseng composition as claimed in claim 1, characterized in that: The parameters of the ultrasonic extraction in step S3 are: power 100W-500W, temperature 40°C-80°C, and time 30min-120min.
8. The method for preparing the flat prostrate chrysanthemum notoginseng composition according to claim 1, characterized in that: The following steps are involved: S1: Pre-treating components including 40wt% of Radix Notoginseng procumbens, 20wt% of Lophatherum gracile, 20wt% of Hovenia dulcis, 10wt% of Celery Seed, 5wt% of Mulberry Leaf, and 5wt% of Puerariae Radix to obtain a raw material powder having a particle size of no more than 0.18 mm; S2: Put tryptophan and ascorbic acid into a reactor at a molar ratio of 1:1, add ultrapure water with a total mass of 1 / 4 of tryptophan and ascorbic acid, stir for 8 hours at a stirring rate of 500 r / min and a stirring temperature of 40°C, then microwave react for 1 hour at a temperature of 40°C, a frequency of 2.4 GHz, and a power of 800 W to obtain a first mixed solution; evaporate the first mixed solution at a temperature of 60°C and a pressure of -0.080 MPa until no distillate is evaporated to obtain a second mixed solution; place the second mixed solution in a vacuum constant temperature drying oven and dry it at a constant temperature of 50°C until the weight is constant, thereby obtaining a low eutectic solvent; S3: The low eutectic solvent is diluted with water to obtain a dilution with a concentration of 30wt%, the raw material powder and the dilution are mixed at a solid-liquid ratio of 1g:30mL, and then ultrasonic extraction is performed with an ultrasonic power of 400W, a temperature set to 50°C, and a processing time of 60min to obtain a plant extract; the plant extract is centrifuged and filtered to obtain a procumbent Chrysanthemum notoginseng composition.
9. Use of a flat chrysanthemum Panax notoginseng composition prepared by the preparation method according to any one of claims 1 to 8 in the preparation of a uric acid-lowering drug, characterized in that: The method comprises using the flat chrysanthemum Panax notoginseng composition as a raw material to prepare an oral preparation for reducing uric acid.
